ERBB2 and non-small cell lung carcinoma: Besides HER2 amplification, clinical trials are ongoing to evaluate the efficacy of anti-HER2 agents in HER2 mutant but not amplified tumors (NCT01670877 in breast cancer and NCT01827267 in non-small cell lung cancer, both with the irreversible tyrosine kinase inhibitor neratinib).